| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Strategic Goals | Strategic Pathways | ||||||||||||||||||||||||||
2 | Message | Prevention | Access to Rapid Diagnosis and Best Treatments | Awareness and Health Literacy | Data and Evidence | Thought Leadership | Global Advocacy | Awareness | Growing the Grassroots | |||||||||||||||||||
3 | Elevator Pitch | Ovarian cancer is a growing global crisis projected to claim nearly 8 million lives by 2050 if we don't take significant action now. Our 5-year impact goal is to achieve significant and equitable improvements in prevention, survival, and quality of life for everyone impacted by ovarian cancer. We will achieve this through four strategic goals: expanding prevention efforts, enhancing access to rapid diagnosis and the best treatments, increasing awareness and health literacy, and advancing data and evidence to inform policy and practice. By fostering strong international partnerships and advocating for global recognition of ovarian cancer as a critical health priority, we can improve outcomes and the quality of life for women worldwide. Each of us has a unique role in driving this global agenda forward, ensuring that everyone living with or at risk of ovarian cancer has the best chance of survival and the best quality of life possible, no matter where they live. | Emphasises the need for expanding prevention efforts globally. | Stresses the importance of improving access to diagnostics and treatments. | Highlights the critical role of raising awareness and improving health literacy. | Calls for the use of data to inform global strategies and measure progress | Focuses on fostering international partnerships and advocating for ovarian cancer as a global priority. | |||||||||||||||||||||
4 | ||||||||||||||||||||||||||||
5 | General Talking Points | Global Ovarian Cancer Crisis | Escalating Mortality: Without significant intervention, nearly 8 million women are projected to die from ovarian cancer by 2050. The annual incidence is expected to increase by 55%, and mortality by 70%, highlighting the critical need for global collaboration and action | Highlights the need for better data to guide global effots and address regional disparities | Calls for global collaboration to address rising incidence and mortality rates | Emphasises the importance of addressing disparities through support for advocacy movements. | ||||||||||||||||||||||
6 | Geographic Disparities: The most significant increases in ovarian cancer cases and deaths are expected in Africa and Asia, regions where healthcare infrastructure and access to diagnostics and treatment require urgent improvemen | |||||||||||||||||||||||||||
7 | ||||||||||||||||||||||||||||
8 | Need for Global Recognition and Action | Global Health Priority: Ovarian cancer must be prioritised within global health agendas, particularly given the rising incidence and mortality rates worldwide. Incorporating ovarian cancer into global women's health initiatives and national cancer control plans is essential | Focuses on ensuring equitable access to care. | Emphasises the importance of incorporating ovarian cancer into broader health initiatives to raise awareness | Advocates for ovarian cancer to be recognised as a global priority. | Emphasises the importance of incorporating ovarian cancer into broader health initiatives to raise awareness | ||||||||||||||||||||||
9 | Equity in Care: Addressing disparities in access to diagnostics, care, and treatment is crucial to ensure all women, regardless of socio-economic status or geographic location, receive the best possible care | |||||||||||||||||||||||||||
10 | ||||||||||||||||||||||||||||
11 | Enhancing Access to Genetic Testing and Treatment | Genetic Testing as Prevention: Expanding access to genetic testing is vital for prevention efforts and personalised treatment of ovarian cancer. Prevention may be especially important in regions with limited access to the best treatments. Increasing awareness about family history and inherited genetic mutations will empower women to take proactive steps in mitigating their risk of ovarian cancer through surveillance or risk reduction measures, including surgery | Highlights the importance of genetic testing as a preventative measure. | Stresses the necessity of equitable access to diagnostics and treatments | Reinforces the need for global partnerships to ensure these resources reach all regions | Reinforces the need for global partnerships to ensure these resources reach all regions | ||||||||||||||||||||||
12 | Ensuring Equitable Access: Emphasising the need for equitable access to both basic and cutting-edge treatments and diagnostics has the potential to significantly reduce mortality rates and improve the quality of life for women with ovarian cancer globally | |||||||||||||||||||||||||||
13 | ||||||||||||||||||||||||||||
14 | The Power of Partnership and Collaboration | Collaborative Impact: By fostering strong partnerships across sectors—including governments, NGOs, research institutions, and the private sector—we can amplify our impact, share vital resources, and accelerate progress toward improving outcomes for women with ovarian cancer globally. This aligns with our strategic pathway of growing the grassroots by fostering advocacy movments and empowering advocacy partners with impactful, high-quality resources and tools. | Partnerships help raise awareness of genetic testing and family history, pushing for policy changes that promote preventive care globally | Collaborations improve access to diagnostics and treatments, ensuring innovative care reaches underserved regions and reduces delays in diagnosis | Cross-sector partnerships amplify awareness campaigns and improve health literacy, ensuring women and healthcare providers are better informed about symptoms and risk factors. | Collaborating with research institutions enhances data collection and drives evidence-based policies, helping close gaps in cancer registries and improve global outcomes | Supports the development of a shared global vision through partnerships | Highlights the importance of cross-sector collaboration to amplify global impact | Emphasises the role of partnerships in building capacity and fostering advocacy movements. | |||||||||||||||||||
15 | ||||||||||||||||||||||||||||
16 | The Importance of Symptom Awareness in Ovarian Cancer Detection | Early Detection Through Awareness: Raising awareness about ovarian cancer risks and symptoms is critical, as it can lead to earlier diagnoses, which is crucial for improving survival rates. Promoting symptom awareness among women and healthcare professionals can reduce the disease burden by enabling earlier, more effective treatment. This is supported by our strategic focus on increasing global awareness and health literacy | By promoting awareness of symptoms, we can contribute to earlier diagnosis and reduce the number of late-stage diagnosis | Directly supports the goal of raising global awareness about ovarian cancer symptoms and the importance of early detection | Underscores the need for accurate data to inform awareness strategies and measure their impact | Directly supports the goal of raising global awareness about ovarian cancer symptoms and the importance of early detection | ||||||||||||||||||||||
17 | ||||||||||||||||||||||||||||
18 | ||||||||||||||||||||||||||||
19 | ||||||||||||||||||||||||||||
20 | ||||||||||||||||||||||||||||
21 | ||||||||||||||||||||||||||||
22 | ||||||||||||||||||||||||||||
23 | ||||||||||||||||||||||||||||
24 | ||||||||||||||||||||||||||||
25 | ||||||||||||||||||||||||||||
26 | ||||||||||||||||||||||||||||
27 | ||||||||||||||||||||||||||||
28 | ||||||||||||||||||||||||||||
29 | ||||||||||||||||||||||||||||
30 | ||||||||||||||||||||||||||||
31 | ||||||||||||||||||||||||||||
32 | ||||||||||||||||||||||||||||
33 | ||||||||||||||||||||||||||||
34 | ||||||||||||||||||||||||||||
35 | ||||||||||||||||||||||||||||
36 | ||||||||||||||||||||||||||||
37 | ||||||||||||||||||||||||||||
38 | ||||||||||||||||||||||||||||
39 | ||||||||||||||||||||||||||||
40 | ||||||||||||||||||||||||||||
41 | ||||||||||||||||||||||||||||
42 | ||||||||||||||||||||||||||||
43 | ||||||||||||||||||||||||||||
44 | ||||||||||||||||||||||||||||
45 | ||||||||||||||||||||||||||||
46 | ||||||||||||||||||||||||||||
47 | ||||||||||||||||||||||||||||
48 | ||||||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||||
50 | ||||||||||||||||||||||||||||
51 | ||||||||||||||||||||||||||||
52 | ||||||||||||||||||||||||||||
53 | ||||||||||||||||||||||||||||
54 | ||||||||||||||||||||||||||||
55 | ||||||||||||||||||||||||||||
56 | ||||||||||||||||||||||||||||
57 | ||||||||||||||||||||||||||||
58 | ||||||||||||||||||||||||||||
59 | ||||||||||||||||||||||||||||
60 | ||||||||||||||||||||||||||||
61 | ||||||||||||||||||||||||||||
62 | ||||||||||||||||||||||||||||
63 | ||||||||||||||||||||||||||||
64 | ||||||||||||||||||||||||||||
65 | ||||||||||||||||||||||||||||
66 | ||||||||||||||||||||||||||||
67 | ||||||||||||||||||||||||||||
68 | ||||||||||||||||||||||||||||
69 | ||||||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||||
71 | ||||||||||||||||||||||||||||
72 | ||||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||||
74 | ||||||||||||||||||||||||||||
75 | ||||||||||||||||||||||||||||
76 | ||||||||||||||||||||||||||||
77 | ||||||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||||
100 | ||||||||||||||||||||||||||||